TY - JOUR
T1 - The future of drug development
T2 - the paradigm shift towards systems therapeutics
AU - Danhof, Meindert
AU - Klein, Kevin
AU - Stolk, Pieter
AU - Aitken, Murray
AU - Leufkens, Hubert
N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.
PY - 2018/12
Y1 - 2018/12
N2 - Progress in cell biology, genetics, molecular, and systems pharmacology is the driving force behind a current paradigm shift in drug research. This paradigm shift shapes new avenues for advanced treatments that are commonly referred to as 'systems therapeutics'. Systems therapeutics differ in many ways from current drugs because they target biological networks rather than single transduction pathways, and affect disease processes rather than physiological processes. Here, we examine how the paradigm shift towards systems therapeutics will change current scientific concepts of the interactions between drugs and diseases, the organization of research and development, as well as the clinical use and therapeutic evaluations of therapeutic interventions.
AB - Progress in cell biology, genetics, molecular, and systems pharmacology is the driving force behind a current paradigm shift in drug research. This paradigm shift shapes new avenues for advanced treatments that are commonly referred to as 'systems therapeutics'. Systems therapeutics differ in many ways from current drugs because they target biological networks rather than single transduction pathways, and affect disease processes rather than physiological processes. Here, we examine how the paradigm shift towards systems therapeutics will change current scientific concepts of the interactions between drugs and diseases, the organization of research and development, as well as the clinical use and therapeutic evaluations of therapeutic interventions.
U2 - 10.1016/j.drudis.2018.09.002
DO - 10.1016/j.drudis.2018.09.002
M3 - Review article
C2 - 30213566
SN - 1359-6446
VL - 23
SP - 1990
EP - 1995
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 12
ER -